$4.95 $0.07 (1.4%)

01:17 PM EST on 12/03/19

BioSyent Inc. (NASDAQOTH:BIOYF)

CAPS Rating: No stars

Current Price $4.95 Mkt Cap $95.1M
Open $4.95 P/E Ratio 20.37
Prev. Close $4.88 Div. (Yield) $0.00 (0.0%)
Daily Range $4.95 - $4.95 Volume 100
52-Wk Range $4.30 - $6.24 Avg. Daily Vol. 3,758

Caps

How do you think NASDAQOTH:BIOYF will perform against the market?

Add Stock to CAPS Watchlist

All Players

5 Outperform
0 Underperform
 

All-Star Players

3 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQOTH:BIOYF Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFPencils (99.86)
Submitted September 04, 2018

BioSyent looks for specialty pharma products that are already commercialized in other markets, like the U.S. or Europe, and then in-licenses or acquires those products to commercialize them in Canada. BioSyent focuses on niche products—with peak… More

SmartAce (99.97)
Submitted June 27, 2019

Shoot for the moon. If you miss, reload and fire again. The moon must be stopped at all costs.

NASDAQOTH:BIOYF VS S&P 500 (SPY)

NASDAQOTH:BIOYF Summary

Fools bullish on NASDAQOTH:BIOYF are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about BIOYF.

Recs

0
Member Avatar freecapital (76.83) Submitted: 9/10/2018 3:16:12 AM : Outperform Start Price: $7.24 NASDAQ OTHER:BIOYF Score: -40.65

dk

Recs

4
Member Avatar TMFPencils (99.86) Submitted: 9/4/2018 10:37:38 AM : Outperform Start Price: $7.24 NASDAQ OTHER:BIOYF Score: -39.79

BioSyent looks for specialty pharma products that are already commercialized in other markets, like the U.S. or Europe, and then in-licenses or acquires those products to commercialize them in Canada. BioSyent focuses on niche products—with peak sales of $20 million or less—that solve an unmet medical need. Not only does this business model give BioSyent a niche that would probably be difficult (or not worthwhile) for competitors to match, but it’s led to strong financial results.

BioSyent hasn’t had any debt on the books since 2001 and hasn’t raised equity since 2002. Today, the company remains debt-free, has over $20 million in cash, and is steadily increasing free cash flow production. The CFO and CEO combined own 17% of shares outstanding.

Management is targeting 20% long-term annualized revenue growth. Currently the market cap sits at $107 million and company trades for less than 25x earnings. Outperform.

Leaderboard

Find the members with the highest scoring picks in BIOYF.

Score Leader

SmartAce

SmartAce (99.97) Score: +12.15

The Score Leader is the player with the highest score across all their picks in BIOYF.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
TMFPencils 99.86 9/4/2018 Outperform 5Y $7.24 -31.63% +8.16% -39.79 3 Comments
redfox18 99.91 9/4/2018 Outperform 5Y $7.26 -31.82% +8.47% -40.29 0 Comment
freecapital 76.83 9/11/2018 Outperform 5Y $7.24 -31.59% +9.06% -40.65 1 Comment
wishyouwell 97.41 9/25/2018 Outperform 5Y $7.50 -33.97% +7.51% -41.47 0 Comment
TMFBoard 40.36 4/18/2018 Outperform 5Y $8.08 -38.74% +17.64% -56.38 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BIOYF.